Teva Pharmaceutical Industries Ltd. has been approved by the Food and Drug Administration for raloxifene tablets (60 mg), a medication for osteoporosis.


Teva, raloxifene tablets, Evista, generic equivalent, Eli Lilly, osteoporosis




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Teva cleared to market Evista generic

March 4th, 2014

JERUSALEM – Teva Pharmaceutical Industries Ltd. has been approved by the Food and Drug Administration for raloxifene tablets (60 mg), a medication for osteoporosis.

The company said Tuesday that its product is a generic equivalent to Eli Lilly & Co.'s Evista tablets in the United States.

Teva noted that it was first to file, making the product eligible for 180 days of marketing exclusivity. The company said it plans to begin shipping the product in the next 30 days.

Evista is used to treat or prevent osteoporosis in postmenopausal women, as well as to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis.

According to IMS Health data reported by Teva, Evista 60-mg tablets had annual sales of approximately $824 million in the United States through December 2013.

Advertisement